Probucol does not inhibit myeloperoxidase-dependent low-density lipoprotein oxidation as a potent protective effect in atherosclerosis

Journal of Cardiovascular Pharmacology

Volumn 50, Issue 3, 2007, Pages 350-351

  Van Antwerpen, Pierre ^a   Nève, Jean ^a   Moreau, Patrick ^a   Boudjeltia, Karim Zouaoui ^a   Vanhaeverbeek, Michel ^a   Prévost, Martine ^a   Babar, Sajida ^a   Legssyer, Ilham ^a   Moguilevsky, Nicole ^b   Ducobu, Jean ^c  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b UNIVERSITY OF NAMUR   (Belgium)

^c Centre Hospitalier Universitaire de Tivoli   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN; MYELOPEROXIDASE; PROBUCOL;

ATHEROSCLEROSIS; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REGULATION; HUMAN; LETTER; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTECTION;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CHLORIDES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYDROGEN PEROXIDE; LIPOPROTEINS, LDL; OXIDATION-REDUCTION; PEROXIDASE; PROBUCOL; TAURINE;

EID: 34548765581     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31809501dc     Document Type: Letter

References (17)

1. Parthasarathy S, Young SG, Witztum JL, et al. Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest. 1986;77:641-644.
2. Kita T, Nagano Y, Yokode M, et al. Probucol prevents the progression of atherosclerosis in Watanabe Heritable Hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA. 1987;84:5928-5932.
3. Sawayama Y, Shimizu C, Maeda N, et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol. 2002;39:610-616.
4. Witting PK, Pettersson K, Letters J, et al. Site-specific anti-atherogenic effect of probucol in apolipoprotein E deficient mice. Arterioscler Thromb Vasc Biol. 2000;20:e26-e33.
5. Yusuf S, Dagenasi G, Pogue J, et al. Vitamin E supplementation and cardiovascular diseases events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:154-160.
6. Choy K, Beck K, Png FY, et al. Processes involved in the site specific effect of probucol on atherosclerosis in apolipoprotein E gene knockout mice. Arterioscler Thromb Vasc Biol. 2005;25:1684-1690.
7. Wu BJ, Kathir K, Witting PK, et al. Antioxidants protects from atherosclerosis by heme oxygenase-1 pathway thatis independent of free radical scavenging. J Exp Med. 2006;203:1117-1127.
8. Witztum JL, Steinberg D. Role of oxidized low-density lipoprotein in atherogenesis. J Clin Invest. 1991;88:1785-1792.
9. Hazen SL, Heinecke JW. Chlorotyrosine, a specific marker of myeloperoxidase-catalysed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest. 1997;99:2075-2081.
10. Heinecke JW. Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis. 1998;141:1-15.
11. Yan LJ, Traber MG, Kobuchi H, et alicacy of hypochlorous acid scavengers in the prevention of protein carbonyl formation. Arch Biochem Biophys. 1996;327:330-334.
12. Hazell LJ, Stocker R. Alpha-tocopherol does not inhibit hypochlorite-induced oxidation of apolipoprotein B-100 of low-density lipoprotein. FEB Lett. 1997;414:541-544.
13. Heinecke JW. Lipoprotein oxidation in cardiovascular disease: chief culprit or innocent bystander? J Exp Med. 2006;203:813-816.
14. Moguilevsky N, Zouaoui Boudjeltia K, Babar S, et al. monoclonal antibodies against LDL progressively oxidized by myeloperoxidase react with ApoB-100 protein moiety and human atherosclerotic lesions. Biochem Biophys Res Comm. 2004;323:1223-1228.
15. Zouaoui Boudjeltia K, Moguilevsky N, Legssyer I, et al. Oxidation of low density lipoproteins by myeloperoxidase at the surface of endothelial cells: an additional mechanism to subendothelium oxidation. Biochem Biophys Res Comm. 2004;325:434-438.
16. 2 / Chloride system to inhibit LDL oxidation. Biochem Biophys Res Comm. 2005;337:82-88.
17. Nève J, Parij N, Moguilevsky N. Inhibition of the myeloperoxidase chlorinating activity by non-steroidal anti-inflammatory drugs investigated with a human recombinant enzyme. Eur J Pharm. 2001;417:37-43.